Clinical Trials Logo

Tachycardia, Ventricular clinical trials

View clinical trials related to Tachycardia, Ventricular.

Filter by:

NCT ID: NCT03871231 Terminated - Clinical trials for Ventricular Tachycardia

Unpinning Termination Therapy for VT/VF

Start date: July 17, 2019
Phase: N/A
Study type: Interventional

This study is intended to develop a better method for stopping potentially lethal heart rhythms than currently available defibrillators. This new method, called Unpinning Termination Therapy (UPT), is hypothesized to be effective in stopping these dangerous heart rhythms at lower voltages and energy than current defibrillators. Consequently, UPT may improve survival, reduce patient pain from shocks, and lead to longer lasting and smaller implantable defibrillators.

NCT ID: NCT03870854 Recruiting - Clinical trials for Ischemic Ventricular Tachycardia (VT)

Paced Electrogram Feature Analysis (PEFA) for Ablation Targeting in Ischaemic Ventricular Tachycardia

PEFA-VT
Start date: August 13, 2019
Phase: N/A
Study type: Interventional

Canadian multicentre prospective cohort study of 40 patients with ischaemic heart disease and therapy from an implantable cardioverter defibrillator (ICD).

NCT ID: NCT03867747 Active, not recruiting - Clinical trials for Ventricular Tachycardia

Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

RAVENTA
Start date: December 2, 2019
Phase: N/A
Study type: Interventional

Patients with refractory ventricular extrasystoles or tachycardia not eligible for catheter ablation will receive single fraction stereotactic body radiation therapy (cardiac radiosurgery) with 25 Gy. Investigators initiated this study to demonstrate that in at least 70% of the patients the planned cardiac radiosurgery may be performed without any interruption or treatment related interventional events within the first 30 days after treatment.

NCT ID: NCT03862989 Withdrawn - Clinical trials for Post-myocardial Infarction Ventricular Tachycardia

Facilitating Catheter Guidance to Optimal Site for VT Ablation

CPS
Start date: May 1, 2021
Phase:
Study type: Observational

Each year in the UK, approximately 150,000 people have a heart attack when the blood supply to their heart is compromised. As a result, affected regions of the heart can become diseased and scarred. In a healthy person, electrical waves propagate across the heart in a regulated pattern which triggers contraction to pump blood around the body. The scar tissue that forms as a result of a heart attack can disrupt the propagation of the electrical waves. If significant disruptions occur, blood cannot be pumped out of the body effectively, leading to sudden death. Ablation therapy aims to eliminate areas of diseased tissue that cause disruption to the heart rhythm, by applying radiofrequency using catheters inserted into the heart. The most accurate techniques used to locate the region to ablate require the induction of dangerous heart rhythms, which are only inducible in about 65% of people. Pace mapping is a technique used to locate regions to ablate, which can be performed during normal heart rhythm. ECG data, which records electrical signals from the heart, is collected when the patient has an abnormal heart rhythm. From this template ECG, a clinician can tell the approximate location of the diseased tissue. A catheter is directed to that location, the heart stimulated, and another ECG, called the paced ECG is recorded. If the paced ECG matches the template ECG, it is assumed that the heart was paced in the location that requires ablation. Current ablation techniques are difficult, time consuming, and inaccurate. As a result, the procedure may work in only half of all patients, and result in unnecessary damage to healthy tissue, leading to later impairment of heart function. The CPS project's overall goal is to increase the success rates of ablation therapy by improving the accuracy and efficiency of locating the optimal region of tissue to eliminate during the pace mapping procedure. Increasing ablation therapy success rates will mean that patients will be unlikely to suffer from future heart rhythm disorders as a result of their heart attack, increasing the life expectancy of heart attack patients. Excess damage caused to the heart as a result of unnecessary ablation lesions will be limited, decreasing the likelihood of future complications. In addition, dangerous heart rhythms do not need to be induced in the patient, significantly decreasing the risk of death during the treatment.

NCT ID: NCT03862339 Completed - Clinical trials for Ventricular Tachycardia

The SoundScar Study The SOUNDSCAR Study

SoundScar
Start date: November 9, 2018
Phase:
Study type: Observational

Prospective, Non-randomized, Single-arm Study to assess the accuracy of intracardiac echocardiography (ICE) for characterization of arrhythmogenic substrate in patients with ischaemic cardiomyopathy undergoing ventricular tachycardia (VT) ablation

NCT ID: NCT03855826 Recruiting - Clinical trials for Ventricular Tachycardia

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Start date: January 15, 2019
Phase: Phase 4
Study type: Interventional

Efficacy and safety evaluation of amiodarone and Nifekalant hydrochloride(NIF) for the treatment of ventricular tachycardia and ventricular fibrillation.

NCT ID: NCT03853369 Recruiting - Clinical trials for Ventricular Tachycardia

Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

Start date: February 18, 2019
Phase:
Study type: Observational

Retrospective and Prospective single arm, observational study to evaluate efficacy and safety of NIF in the treatment of ventricular tachycardia and ventricular fibrillation. The information registration of the target population will be collected with the hospital HIS system or LIS system.

NCT ID: NCT03833089 Recruiting - Atrial Fibrillation Clinical Trials

Targeted Potassium Levels for Prevention of ICD Therapy

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates whether a rigorously controlled high-normal level of serum-potassium (4.5-5.0 mEq/L) using dietary recommendations, potassium supplements and mineralocorticoid receptor antagonists will results in a lower incidence of cardiac arrhythmias in patients with an ICD. Patients will be randomized to this treatment or a control arm, where patients will receive usual guideline recommended follow-up.

NCT ID: NCT03826524 Recruiting - Clinical trials for Ventricular Fibrillation

Epinephrine Dose: Optimal Versus Standard Evaluation Trial

EpiDOSE
Start date: May 24, 2023
Phase: Phase 4
Study type: Interventional

The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients.

NCT ID: NCT03819504 Withdrawn - Clinical trials for Ventricular Tachycardia

Stereotactic Non-invasive Ablation of Ventricular Tachycardia

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

STereotactic Ablative Radiosurgery of recurrent Ventricular Tachycardia in structural heart disease (STAR-VT).